TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14609301

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 1200 mg daily (3 times 400 mg) for 120 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 40
Study: 10513096

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (combined distant and local acupoints)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional drug treatment
Number of subjects: 64
Study: 8233387

Group type: EXPERIMENTAL
Intervention: Silicone oil
Number of subjects: 241

Group type: COMPARATOR
Intervention: C3F8 gas
Number of subjects: 241
Study: 3689627

Group type: EXPERIMENTAL
Intervention: CGS 14824 A (20 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nicardipine (cumulative doses of 1.25, 3.75, and 8.75 mg)
Number of subjects: 8
Study: 29654039

Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT)
Number of subjects: 464

Group type: COMPARATOR
Intervention: Standard dressing (control)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Follow-up at 4 months
Number of subjects: 464
Study: 27466360

Group type: EXPERIMENTAL
Intervention: PHE expansion rate (0.31 mL/hour, IQR 0.12-0.55)
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: PHE expansion rate
Number of subjects: 596
Study: 25828327

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 5433

Group type: EXPERIMENTAL
Intervention: PCI/CABG
Number of subjects: 5433

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 5433
Study: 23453547

Group type: EXPERIMENTAL
Intervention: Early enteral fat supplement and fish oil
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 36
Study: 22287402

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg o.i.d), amoxicillin (1 g b.i.d) and proton pump inhibitor (b.i.d) for 10 days (Group 1, n=60)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg b.i.d), amoxicillin (1 g b.i.d) and proton pump inhibitor (b.i.d) for 10 days (Group 2, n=50)
Number of subjects: 110
Study: 19361602

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (1.5 microg/kg every 20 days for 3 months) plus oral iron
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo plus oral iron
Number of subjects: 30
Study: 16638740

Group type: EXPERIMENTAL
Intervention: Ritonavir (200 mg; 4 doses over 2 days)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 7
Study: 15571616

Group type: EXPERIMENTAL
Intervention: Pure cut setting
Number of subjects: 49

Group type: COMPARATOR
Intervention: Blend setting
Number of subjects: 49
Study: 11585680

Group type: EXPERIMENTAL
Intervention: Subcutaneous IL‐2 alone (n=13)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: IL‐2 + IFN‐alpha (n=5)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Low-dose IFN‐alpha alone (n=5)
Number of subjects: 33

Group type: COMPARATOR
Intervention: High-dose IFN‐alpha alone (n=10)
Number of subjects: 33
Study: 10408812

Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg/ml
Number of subjects: 122

Group type: COMPARATOR
Intervention: Bupivacaine 5 mg/ml
Number of subjects: 122
Study: 7853279

Group type: EXPERIMENTAL
Intervention: Pregnancies with cerclage (58 pregnancies)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Pregnancies without cerclage (52 pregnancies)
Number of subjects: 35
Study: 2571327

Group type: EXPERIMENTAL
Intervention: 0.017% levobunolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.05% levobunolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.167% levobunolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.017% betaxolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.05% betaxolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.167% betaxolol
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.5% betaxolol
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study: 1095046

Group type: EXPERIMENTAL
Intervention: Doxapram
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31416763

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg pro re nata
Number of subjects: 217
Study: 31169077

Group type: EXPERIMENTAL
Intervention: E-cigarette use
Number of subjects: 456

Group type: COMPARATOR
Intervention: Cessation pharmacotherapy
Number of subjects: 456
Study: 28719527

Group type: EXPERIMENTAL
Intervention: Pupillometry-guided remifentanil administration
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard remifentanil administration
Number of subjects: 55
Study: 25760354

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion threshold (hemoglobin level <7.5 g per deciliter)
Number of subjects: 2007

Group type: COMPARATOR
Intervention: Liberal transfusion threshold (hemoglobin level <9 g per deciliter)
Number of subjects: 2007

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion threshold
Number of subjects: 2007

Group type: COMPARATOR
Intervention: Liberal transfusion threshold
Number of subjects: 2007
Study: 23727832

Group type: EXPERIMENTAL
Intervention: Manual bisection of solid lines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual bisection of letter lines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisection by eye fixation of letter lines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bisection by eye fixation of solid lines
Number of subjects: 0
Study: 22205952

Group type: EXPERIMENTAL
Intervention: Fetal movement counting from gestational week 28
Number of subjects: 1076

Group type: COMPARATOR
Intervention: Standard antenatal care not including fetal movement counting
Number of subjects: 1076
Study: 18663295

Group type: EXPERIMENTAL
Intervention: Acetyl‐DL‐leucine
Number of subjects: 0
Study: 16817839

Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg o.d.
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg o.d.
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.d.
Number of subjects: 595
Study: 12799312

Group type: EXPERIMENTAL
Intervention: Intravenous C-peptide
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intravenous C-peptide during NOS blockade
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intra-arterial C-peptide during NOS blockade
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: C-peptide after recovery from NOS blockade
Number of subjects: 11
Study: 11060747

Group type: EXPERIMENTAL
Intervention: Insulin sensitiser drugs
Number of subjects: 0
Study: 9087576

Group type: EXPERIMENTAL
Intervention: Cold crystalloid cardioplegic solution
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cold blood cardioplegic solution
Number of subjects: 28
Study: 8328549

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tetracycline hydrochloride 1 g/day
Number of subjects: 24
Study: 3080289

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29880175

Group type: EXPERIMENTAL
Intervention: 3 mg drospirenone/30 μg ethinyl estradiol (OC)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Combination of OC and 1700 mg metformin
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: 1700 mg metformin
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 87
Study: 26950683

Group type: EXPERIMENTAL
Intervention: 5 g transdermal T gel (TT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 1 mg oral aromatase inhibitor (AI)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 24874317

Group type: EXPERIMENTAL
Intervention: Tenoxicam (texamen) 20 mg daily for 7 days with therapeutic exercises
Number of subjects: 50

Group type: COMPARATOR
Intervention: Myorelaxants and massage of cervical-collar zone
Number of subjects: 50
Study: 22220822

Group type: EXPERIMENTAL
Intervention: Amoxicillin-metronidazole combination (500 mg of each, three times a day for 7 days) and One-Stage-Full-Mouth-Disinfection (OSFMD)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo and One-Stage-Full-Mouth-Disinfection (OSFMD)
Number of subjects: 39
Study: 20484967

Group type: EXPERIMENTAL
Intervention: Standardized tape stripping (SPT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Subgroup of 18 subjects for interrater agreement
Number of subjects: 75
Study: 18382081

Group type: EXPERIMENTAL
Intervention: Oat bran for 12 weeks (fiber group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no oat bran)
Number of subjects: 30
Study: 15760651

Group type: EXPERIMENTAL
Intervention: Vinpocetine (n=6)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (n=7)
Number of subjects: 13
Study: 12443955

Group type: EXPERIMENTAL
Intervention: Shock absorbing insoles (two types)
Number of subjects: 9

Group type: COMPARATOR
Intervention: No insole (control)
Number of subjects: 9
Study: 10500075

Group type: EXPERIMENTAL
Intervention: UDCA plus budesonide (3 mg three times daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: UDCA plus placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: UDCA plus budesonide
Number of subjects: 39
Study: 8934801

Group type: EXPERIMENTAL
Intervention: Astemizole 10 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1898300

Group type: EXPERIMENTAL
Intervention: Aspartame (50 mg/kg body weight)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Ethanol (0.1% BAL)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 7129725

Group type: EXPERIMENTAL
Intervention: Heating treatment at 45 degrees C
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-heated condition
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Heated condition
Number of subjects: 10
Study: 31615569

Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression model to predict 90-day readmission risk
Number of subjects: 350
Study: 27858987

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 10 mg BID (n=54)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Hydroxycarbamide (n=56)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (post hoc analysis)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Hydroxycarbamide (post hoc analysis)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (after unblinding)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Hydroxycarbamide
Number of subjects: 110
Study: 25926739

Group type: EXPERIMENTAL
Intervention: BPLab® sphygmomanometer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mercury sphygmomanometry
Number of subjects: 30
Study: 24461370

Group type: EXPERIMENTAL
Intervention: Web-based delivery
Number of subjects: 73

Group type: COMPARATOR
Intervention: Telehealth-based delivery
Number of subjects: 73
Study: 21883458

Group type: EXPERIMENTAL
Intervention: Morning measurements
Number of subjects: 51

Group type: COMPARATOR
Intervention: Afternoon measurements
Number of subjects: 51
Study: 19281327

Group type: EXPERIMENTAL
Intervention: Empirical antifungal treatment (amphotericin B deoxycholate 1 mg/kg/day or liposomal amphotericin 3 mg/kg/day)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Preemptive antifungal treatment (amphotericin B deoxycholate 1 mg/kg/day or liposomal amphotericin 3 mg/kg/day)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Preemptive antifungal treatment
Number of subjects: 293
Study: 17290726

Group type: EXPERIMENTAL
Intervention: Nicotine inhaler
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Both nicotine inhaler and bupropion
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Bupropion (phase 2 trial)
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Nicotine inhaler (phase 2 trial)
Number of subjects: 1700

Group type: EXPERIMENTAL
Intervention: Combination therapy (nicotine inhaler and bupropion)
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Nicotine inhaler re-treated with bupropion
Number of subjects: 1700

Group type: COMPARATOR
Intervention: Bupropion re-treated with nicotine inhaler
Number of subjects: 1700
Study: 15318311

Group type: COMPARATOR
Intervention: Healthy adults (Group A)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Children (Group B)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Patients with normal albuminuria (Group C)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Patients with microalbuminuria (Group D)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Patients with macroalbuminuria (Group E)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Patients with a well-functioning transplanted kidney (Group F)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Patients with suspected acute rejection (Group G)
Number of subjects: 86
Study: 11771440

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation therapy following complete resection of gastric cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy following resection of stage III colon cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiation therapy for stages II and III rectal cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation therapy for esophageal cancer
Number of subjects: 0
Study: 9158353

Group type: EXPERIMENTAL
Intervention: Meperidine (0.6 microgram/ml, 40 mg/h)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Meperidine (1.8 micrograms/ml, 120 mg/h)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no opioid)
Number of subjects: 9
Study: 8362195

Group type: EXPERIMENTAL
Intervention: 0.3% triclosan + 1.5% sodium lauryl sulfate (SLS)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 0.15% triclosan + 1.5% sodium lauryl sulfate (SLS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 1.5% sodium lauryl sulfate (SLS)
Number of subjects: 11
Study: 3318475

Group type: EXPERIMENTAL
Intervention: timolol 0.5%-pilocarpine 2% twice a day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: timolol 0.5%-pilocarpine 4% twice a day
Number of subjects: 25

Group type: COMPARATOR
Intervention: pilocarpine 4% four times a day
Number of subjects: 25
Study: 31217008

Group type: EXPERIMENTAL
Intervention: Facebook
Number of subjects: 2394

Group type: EXPERIMENTAL
Intervention: E-mail
Number of subjects: 2394

Group type: EXPERIMENTAL
Intervention: WhatsApp
Number of subjects: 2394

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 2394
Study: 29911355

Group type: EXPERIMENTAL
Intervention: Intensive glycemia treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary outcome
Number of subjects: 0
Study: 27061162

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 18
Study: 24647511

Group type: EXPERIMENTAL
Intervention: Four weeks of immobilization
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Eight weeks of immobilization
Number of subjects: 100

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 100
Study: 23098680

Group type: EXPERIMENTAL
Intervention: Melatonin (0.5 mg, 2 mg, 6 mg, 12 mg)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 20647477

Group type: EXPERIMENTAL
Intervention: Particle-mediated epidermal delivery (PMED) with 4 microg mouse gp100 DNA
Number of subjects: 27

Group type: COMPARATOR
Intervention: Intramuscular (i.m.) injection with 2,000 microg mouse gp100 DNA
Number of subjects: 27
Study: 18704636

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m² on days 1, 8, and 15 of a 28-day cycle
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m² (with dose reduction to 800 mg/m² in 5 patients due to toxicity)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m²
Number of subjects: 28
Study: 15965168

Group type: COMPARATOR
Intervention: Classic laser treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Light laser treatment
Number of subjects: 24
Study: 14651353

Group type: EXPERIMENTAL
Intervention: Direct Radionuclide Cystography (DRNC)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Voiding Cystourethrography (VCUG)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both DRNC and VCUG
Number of subjects: 25
Study: 10557021

Group type: EXPERIMENTAL
Intervention: Sibutramine (15mg/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 8916634

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Relapse prevention therapy
Number of subjects: 97

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 1679254

Group type: EXPERIMENTAL
Intervention: Continuous low dose antipsychotic medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent or targeted medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Established moderate dose antipsychotic medication
Number of subjects: 0
Study: 6341252

Group type: EXPERIMENTAL
Intervention: Cefroxadine (1 g t.i.d. for five days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cephalexin (1 g t.i.d. for five days)
Number of subjects: 0
Study: 31113752

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 250 mg twice daily for 6 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no prophylactic treatment)
Number of subjects: 200
Study: 27754790

Group type: EXPERIMENTAL
Intervention: Antireflux stent (ARS); n=6
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional plastic stent; n=7
Number of subjects: 13
Study: 26797555

Group type: EXPERIMENTAL
Intervention: Noisy intraoperative environment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Quiet intraoperative environment
Number of subjects: 20
Study: 24259653

Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg (1-hour infusion) every 8 hours
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Meropenem 1 g (0.5-hour infusion) every 8 hours
Number of subjects: 20
Study: 22546317

Group type: EXPERIMENTAL
Intervention: Ozioma News Service
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control newspapers
Number of subjects: 24
Study: 20131578

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional rehabilitation
Number of subjects: 0
Study: 17986324

Group type: EXPERIMENTAL
Intervention: Local injection of 20 ml Carbostesin 0.25% at the end of the operation
Number of subjects: 264

Group type: COMPARATOR
Intervention: 20 ml placebo (0.9% Saline) injection
Number of subjects: 264
Study: 15994611

Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 101

Group type: COMPARATOR
Intervention: Discharged home
Number of subjects: 101
Study: 12668574

Group type: EXPERIMENTAL
Intervention: Indinavir 800 mg every 8 h
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Indinavir 800 mg + ritonavir 100 mg every 12 h
Number of subjects: 36
Study: 10320251

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (0.5 microg x kg(‐1) x min(‐1))
Number of subjects: 22
Study: 9604487

Group type: EXPERIMENTAL
Intervention: Omeraz®
Number of subjects: 22

Group type: COMPARATOR
Intervention: Losec®
Number of subjects: 22
Study: 1866408

Group type: EXPERIMENTAL
Intervention: nCPAP-therapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Theophylline 375-400 mg in the evening
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: O2-therapy by 21/min, by nasal prongs
Number of subjects: 21
Study: 6406165

Group type: EXPERIMENTAL
Intervention: High-calorie and protein supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31873856

Group type: EXPERIMENTAL
Intervention: Breast cancer screening program
Number of subjects: 318
Study: 29186319

Group type: COMPARATOR
Intervention: i.v. carboplatin/paclitaxel
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: i.p. carboplatin plus i.v./i.p. paclitaxel
Number of subjects: 275
Study: 27657476

Group type: EXPERIMENTAL
Intervention: High dose diuretics (HD)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Low diuretic efficiency (DE)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Continuous administration
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Worsening renal function (WRF)
Number of subjects: 96
Study: 25689128

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Vesicoamniotic shunting (VAS)
Number of subjects: 45
Study: 24312305

Group type: EXPERIMENTAL
Intervention: High-exposure group (antimicrobial treatment with piperacillin/tazobactam, meropenem, ciprofloxacin)
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Standard-of-care (SOC group, antimicrobial treatment with cefuroxime)
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 1147
Study: 20374604

Group type: EXPERIMENTAL
Intervention: Cosmetic regimen (n = 99): SPF 30 moisturizing lotion with 5% niacinamide, peptides, antioxidants; moisturizing cream with niacinamide and peptides; targeted wrinkle product with niacinamide, peptides, and 0.3% retinyl propionate
Number of subjects: 196

Group type: COMPARATOR
Intervention: Prescription regimen (n = 97): 0.02% tretinoin plus moisturizing SPF 30 sunscreen
Number of subjects: 196
Study: 18177635

Group type: EXPERIMENTAL
Intervention: Teaching events designed according to the explanation-based learning (EBL) account
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modified teaching events that removed one of the EBL steps
Number of subjects: 0
Study: 17712656

Group type: EXPERIMENTAL
Intervention: Tranexamic acid 1000 mg, twice daily
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Tranexamic acid 500 mg, twice daily
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study: 12672536

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control-mixture ingestion
Number of subjects: 13
Study: 10759664

Group type: EXPERIMENTAL
Intervention: Terazosin (1-2 mg daily, 0.5 mg twice daily for 2 weeks, then 1 mg twice daily for 2 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Tamsulosin (0.2 mg daily for 4 weeks)
Number of subjects: 61